Roche Holding AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
A Proof of Concept Study of the Safety, Tolerability, and Efficacy of Avastin (Bevacizumab) in Patients With Chemo-naive Chronic Lymphocytic Leukemia
- First Posted Date
- 2008-09-18
- Last Posted Date
- 2014-06-26
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 2
- Registration Number
- NCT00754650
An Exploratory Study of Tocilizumab in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Current Non-Biologic DMARDs and/or Anti-TNF Therapy.
- First Posted Date
- 2008-09-11
- Last Posted Date
- 2015-07-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1681
- Registration Number
- NCT00750880
A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Plus Pioglitazone.
Phase 3
Completed
- Conditions
- Diabetes Mellitus Type 2
- Interventions
- First Posted Date
- 2008-09-01
- Last Posted Date
- 2016-08-05
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 326
- Registration Number
- NCT00744367
A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise.
- First Posted Date
- 2008-09-01
- Last Posted Date
- 2016-07-28
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 373
- Registration Number
- NCT00744926
A Study of MabThera (Rituximab) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia.
Phase 2
Completed
- Conditions
- Lymphocytic Leukemia, Chronic
- Interventions
- First Posted Date
- 2008-08-20
- Last Posted Date
- 2017-08-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 97
- Registration Number
- NCT00738374
- Locations
- 🇮🇹
Ospedale Cardarelli; Divisione Di Ematologia, Napoli, Campania, Italy
🇮🇹A.O. Universitaria Policlinico S.Orsola-Malpighi Di Bologna, Bologna, Emilia-Romagna, Italy
🇮🇹Arcispedale S. Anna; Sezione Di Ematologia, Ferrara, Emilia-Romagna, Italy
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy
Phase 3
Completed
- Conditions
- Renal Cell Cancer
- Interventions
- First Posted Date
- 2008-08-20
- Last Posted Date
- 2016-06-23
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 649
- Registration Number
- NCT00738530
A Study of Once Monthly Intravenous Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.
Phase 4
Completed
- Conditions
- Anemia
- Interventions
- Drug: methoxy polyethylene glycol-epoetin beta [Mircera]
- First Posted Date
- 2008-08-19
- Last Posted Date
- 2017-12-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 132
- Registration Number
- NCT00737464
- Locations
- 🇮🇳
Nizam's Institute of Medical Sciences; Nephrology, Hyderabad, India
🇮🇳Wockhardt Hospital and Kidney Institute; Nephrology, Kolkata, India
🇮🇳Meerut Kidney Hospital, Meerut, India
A Study of Monthly Subcutaneous (SC) Mircera for Maintenance Treatment of Participants With Chronic Kidney Disease on Peritoneal Dialysis
- First Posted Date
- 2008-08-19
- Last Posted Date
- 2017-06-23
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 96
- Registration Number
- NCT00737477
- Locations
- 🇫🇷
Arauco; Arauco Tours Bretonneau, Tours, France
🇫🇷Centre Hospitalier; Hemodialyse, Annonay, France
🇫🇷Ch Notre Dame Misericorde; Hemodialyse, Ajaccio, France
A Study of Two-Weekly Intravenous Mircera for the Treatment of Dialysis Patients With Chronic Renal Anemia Not Receiving ESA Therapy.
Phase 4
Completed
- Conditions
- Anemia
- Interventions
- Drug: methoxy polyethylene glycol-epoetin beta [Mircera]
- First Posted Date
- 2008-08-19
- Last Posted Date
- 2016-06-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 189
- Registration Number
- NCT00737711
A Dose-Escalation Study of RO5083945 in Patients With Metastatic and/or Locally Advanced Malignant Epidermal Growth Factor Receptor (EGFR)+ Solid Tumors.
Phase 1
Completed
- Conditions
- Neoplasms
- Interventions
- Drug: RO5083945
- First Posted Date
- 2008-07-24
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 102
- Registration Number
- NCT00721266
© Copyright 2025. All Rights Reserved by MedPath